• Home
  • Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

Author List
Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M
Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1423768
Publication Year
2001
PubMed ID
11230472
Publication Title
Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001 Mar 01; 19(5):1304-11.